GLIOBLASTOMA MULTIFORME: CURRENT CHALLENGES IN DIAGNOSIS, TREATMENT, AND FUTURE THERAPEUTIC STRATEGIES

2th-year student of the Faculty of Pediatrics,
Murodillayeva Ruxshona Jasurbek qizi
4th-year students of the Faculty of General Medicine,
Tirkashev Adxam Uktamjonovich
Iskandarova Bahora Bektosh qizi
Ergasheva Fotima Anvar qizi
Samarkand State Medical University
https://doi.org/10.5281/zenodo.20622752

Abstract

Glioblastoma multiforme (GBM) is the most aggressive and common primary malignant brain tumor in adults. Despite significant advances in neuro-oncology, neurosurgery, molecular biology, and medical imaging, glioblastoma remains associated with poor prognosis and high mortality rates. The tumor is characterized by rapid growth, extensive infiltration into surrounding brain tissue, marked genetic heterogeneity, and resistance to conventional therapies. Current treatment typically involves maximal surgical resection followed by radiotherapy and chemotherapy; however, recurrence is almost inevitable. Recent developments in molecular diagnostics, immunotherapy, targeted therapies, and gene-based treatments have generated new hope for improving outcomes. This article reviews the pathogenesis, epidemiology, clinical manifestations, diagnostic challenges, treatment approaches, and future therapeutic strategies for glioblastoma multiforme.

Keywords

Glioblastoma multiforme; glioblastoma; brain tumor; neuro-oncology; magnetic resonance imaging; immunotherapy; targeted therapy; molecular biomarkers; neurosurgery.

Introduction

Glioblastoma multiforme is the most common and most aggressive malignant primary brain tumor originating from glial cells. It belongs to the group of high-grade gliomas and is classified as a Grade 4 diffuse glioma according to modern neuropathological classifications.

Despite extensive research efforts, glioblastoma continues to pose one of the greatest challenges in neuro-oncology. The disease is characterized by rapid progression, diffuse invasion of brain tissue, resistance to treatment, and frequent recurrence. Median survival remains limited even with optimal multimodal therapy.

The complexity of glioblastoma biology, combined with its critical anatomical location within the central nervous system, makes successful treatment particularly difficult. Consequently, there is an urgent need for innovative diagnostic tools and more effective therapeutic approaches.

Epidemiology and Risk Factors

Glioblastoma accounts for approximately half of all malignant primary brain tumors in adults. The disease predominantly affects individuals between the ages of 50 and 75 years, although it can occur at any age.

The incidence of glioblastoma is slightly higher in males than in females. While the exact etiology remains largely unknown, several risk factors have been identified. Exposure to ionizing radiation is the most well-established environmental risk factor associated with glioblastoma development.

Certain inherited genetic syndromes may increase susceptibility to glioma formation, although most cases occur sporadically without a clear hereditary pattern. Ongoing research continues to investigate the role of genetic, environmental, and molecular factors in tumor initiation and progression.

Pathogenesis and Molecular Characteristics

The biological behavior of glioblastoma is driven by complex molecular and genetic alterations. These changes affect cellular proliferation, apoptosis, angiogenesis, invasion, and immune regulation.

One of the defining characteristics of glioblastoma is extensive genetic heterogeneity. Different regions within the same tumor may possess distinct molecular profiles, contributing to treatment resistance and disease recurrence.

Glioblastoma cells exhibit uncontrolled proliferation and infiltrative growth patterns that extend beyond radiologically visible tumor margins. This diffuse invasion makes complete surgical removal virtually impossible.

Another hallmark feature is the formation of abnormal blood vessels through angiogenesis. The tumor stimulates the development of new vascular networks to support rapid growth, contributing to its aggressive clinical behavior.

Recent advances in molecular pathology have enabled more precise classification of glioblastoma subtypes and have provided valuable insights into prognostic factors and therapeutic targets.

Clinical Manifestations

The clinical presentation of glioblastoma depends on tumor size, growth rate, and anatomical location within the brain.

Headache is among the most common presenting symptoms and may result from increased intracranial pressure. Patients frequently experience progressive neurological deficits such as weakness, sensory disturbances, visual impairment, language dysfunction, or cognitive decline.

Seizures are another common manifestation, particularly when tumors involve cortical regions. Changes in personality, memory impairment, and behavioral disturbances may also occur as the disease progresses.

Symptoms often worsen rapidly due to the highly aggressive nature of the tumor. Consequently, prompt evaluation and diagnosis are essential for initiating treatment and minimizing neurological deterioration.

Challenges in Diagnosis

Accurate diagnosis of glioblastoma requires integration of clinical, radiological, and pathological findings.

Neuroimaging plays a central role in the diagnostic process. Advanced imaging techniques provide detailed information regarding tumor location, extent, vascularity, and surrounding tissue involvement. Modern imaging modalities also assist in treatment planning and postoperative monitoring.

Histopathological examination remains the gold standard for definitive diagnosis. Tissue samples obtained through biopsy or surgical resection allow microscopic evaluation and molecular characterization of the tumor.

One of the major diagnostic challenges is distinguishing tumor progression from treatment-related changes. Advanced imaging technologies and molecular biomarkers are increasingly being utilized to improve diagnostic accuracy and disease monitoring.

Early and precise diagnosis is critical because treatment decisions and prognosis depend heavily on accurate tumor characterization.

Current Treatment Approaches

The standard treatment for newly diagnosed glioblastoma involves a multimodal strategy consisting of surgery, radiotherapy, and chemotherapy.

Surgical Management

Maximal safe surgical resection is typically the first step in treatment. The primary objectives are to reduce tumor burden, relieve symptoms, obtain tissue for diagnosis, and improve the effectiveness of subsequent therapies.

However, complete removal is rarely achievable because glioblastoma cells infiltrate normal brain tissue beyond visible tumor boundaries. Neurosurgeons must balance aggressive tumor resection with preservation of neurological function.

Radiotherapy

Radiotherapy remains a cornerstone of glioblastoma treatment. Following surgery, targeted radiation is used to destroy residual tumor cells and delay disease progression.

Modern radiotherapy techniques allow more precise delivery of radiation while minimizing damage to surrounding healthy brain tissue.

Chemotherapy

Chemotherapy is commonly administered in combination with radiotherapy and as maintenance treatment thereafter. This combined approach has become the standard of care and has modestly improved survival outcomes.

Despite these advances, therapeutic resistance remains a major obstacle, and tumor recurrence occurs in the vast majority of patients.

Emerging Therapeutic Strategies

The limitations of conventional treatments have stimulated extensive research into novel therapeutic approaches.

Targeted Therapy

Advances in molecular biology have enabled the development of therapies aimed at specific genetic and signaling abnormalities within tumor cells. Personalized treatment strategies based on molecular profiling may improve therapeutic effectiveness in selected patients.

Immunotherapy

Immunotherapy seeks to harness the body's immune system to recognize and destroy cancer cells. Various immunotherapeutic approaches, including immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies, are currently under investigation.

Although results have been mixed, immunotherapy remains one of the most promising areas of glioblastoma research.

Gene Therapy

Gene-based therapies aim to modify or correct molecular abnormalities responsible for tumor growth. Experimental studies suggest that these approaches may offer new opportunities for targeting treatment-resistant tumor populations.

Artificial Intelligence and Precision Medicine

Artificial intelligence is increasingly being applied to neuro-oncology for diagnostic interpretation, prognostic assessment, treatment planning, and outcome prediction. Integration of genomic data and advanced computational methods may facilitate highly individualized therapeutic strategies in the future.

Future Perspectives

Future progress in glioblastoma management will depend on a deeper understanding of tumor biology and the development of innovative therapeutic technologies.

Precision medicine approaches integrating molecular profiling, advanced imaging, and personalized treatment algorithms are expected to play an increasingly important role. Combination therapies targeting multiple biological pathways simultaneously may improve treatment response and reduce recurrence.

Continued advances in immunotherapy, gene editing, nanotechnology, and regenerative medicine offer additional opportunities for improving survival and quality of life. International collaboration and large-scale clinical research will be essential for translating scientific discoveries into effective clinical practice.

Conclusion

Glioblastoma multiforme remains one of the most challenging malignancies in modern medicine due to its aggressive growth, extensive infiltration, molecular complexity, and resistance to treatment. Despite advances in surgery, radiotherapy, and chemotherapy, long-term survival remains limited.

Recent developments in molecular diagnostics, targeted therapy, immunotherapy, and precision medicine have expanded our understanding of the disease and created new possibilities for treatment. Although significant obstacles remain, ongoing scientific innovation provides hope for more effective therapeutic strategies and improved patient outcomes in the future.

References

Uzbek Literature

1. Rahimov, R.A. Neyroxirurgiya asoslari. Toshkent: Yangi asr avlodi, 2021.
2. Karimov, H.Q. Klinik onkologiya va neyroonkologiya. Toshkent: Abu Ali ibn Sino nomidagi Tibbiyot nashriyoti, 2020.
3. Mamatqulov, M.A. Patologik anatomiya va markaziy nerv tizimi o‘smalari. Toshkent: Fan va texnologiya, 2019.

International Literature

4. National Cancer Institute. Glioblastoma Treatment and Research Updates. Bethesda, 2024.
5. European Association of Neuro-Oncology. Guidelines for the Diagnosis and Treatment of Glioblastoma. 2024.